cutaneous T cell lymphoma

(redirected from Cutaneous T-cell lymphomas)

cutaneous T cell lymphoma

Mycosis fungoides Oncology A heterogeneous group of relatively uncommon NHLs, which first appear on the skin Epidemiology ±1000 cases occur/yr, US, affecting ages 50-60; ♂:♀ ratio, 2:1; black:white, 2:1 Clinical Long–4-10 yrs Hx of eczematous rashes, which may evolve to parapsoriasis en plaque or poikiloderma atrophicans vasculare  Pathology Epidermotropism, paracortical proliferation in lymph nodes, periarterial proliferation in spleen; aggregates of epithelioid cells, prominent vascular channels, BM involvement Management Nitrogen mustard, BCNU, PUVA therapy, RT Response rate 80% if T1; 30–60% if T2; 20% if T3. See Redman syndrome, Sézary syndrome.
References in periodicals archive ?
Common skin cancers include basal cell and squamous cell carcinomas, Kaposi's sarcomas, adnexal tumors, and cutaneous T-cell lymphomas.
Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome).
Cutaneous T-cell lymphomas are a group of lymphomas characterized by abnormal accumulation of malignant T-cells in the skin, potentially resulting in the development of rashes, plaques and tumors.
Recombinant human interleukin-12 induces lesion regression in some cutaneous T-cell lymphomas, reported Dr.
Based on these results, Allos intends to continue investigating the role of FOLOTYN as an option for patients with cutaneous T-cell lymphomas.
Cutaneous T-cell lymphomas (CTCL) are a group of lymphomas characterized by abnormal accumulation of malignant T-cells in the skin, resulting in the development of rashes, plaques and tumors.
Cutaneous T-cell lymphomas, or CTCLs, are comprised of a number of indolent non-Hodgkin's T-cell lymphomas, including mycosis fungoides and Sezary syndrome, which have their primary manifestations in the skin.
Cutaneous T-cell lymphomas, or CTCLs, are comprised of a number of non-Hodgkin's T-cell lymphomas, including mycosis fungoides and Sezary syndrome, which have their primary manifestations in the skin.
Due to their heterogeneity, there are no universally applicable guidelines available for the treatment of cutaneous T-Cell lymphomas.
Genmab A/S (CSE: GEN) announced today positive early results of the first stage of the ongoing pivotal Phase III study of HuMax-CD4(R) (zanolimumab) in cutaneous T-cell lymphoma (CTCL) and the ongoing Phase II study in non-cutaneous T-cell lymphoma (NCTCL).
HuMax-CD4 Currently in Phase III Clinical Trial for Cutaneous T-Cell Lymphoma and Phase II Clinical Trial for Non-Cutaneous T-Cell Lymphoma
Genmab A/S (CSE: GEN) announced today that 55% of higher dose patients in the primary indication (10/18) achieved at least a partial response in HuMax-CD4 Phase II cutaneous T-cell lymphoma (CTCL) studies.